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The purpose of this research project is to create TALEs that will activate the 
betaglobin gene so that the mRNA can be detected using molecular beacons. The reason 
we need to upregulate or activate the gene is that during sickle cell anemia the gene is 
mutated. In regular cell lines the betaglobin gene is not activated, so to test our 
hypothesis we need to activate the gene in the cells to be able to test our gene therapies. 
We are using TALEs so that we can enter the nucleus, bind effector-specific DNA 
sequences, and transcriptionally activate gene expression. This allows us to later on use 
TALENs to cut the specific parts that we do not want in the DNA. This research is under 
the mentorship of Eli Fine in the Biomedical Engineering department and Dr. Gang Bao 






 This research is particularly important to Sickle Cell Anemia, but also for other 
genetic diseases. As this is relatively new research, most of the research is more specific 
to the structure of TALEs and certain genes instead of actual TALEs involved in 
diseases. As mentioned before, the sickled cells in Sickle cell anemia occur because of 
mutations in the beta globin gene of the red blood cells. Our research is to upregulate or 
activate the beta globin gene in these cells. The reason for this is because we want the 
RNA of the beta globin gene. We need that RNA so that we can detect it with Molecular 
Beacons and find its exact location. In order to transcribe the beta globin DNA into RNA, 
we need to first activate or “turn on” the transcription of that gene within the cell. Once a 
gene is activated then we will be able to use the molecular beacons to detect the specific 
sequence that we want in the nucleic acid. By constructing the TALEs that can do this, 














The research on Transcription Activator-like Effectors has increased in recent years. 
The research went from Homing Endonucleases to Zinc Finger Nucleases to TALEs and 
TALENs. Homing Endonucleases are naturally occurring sequence-specific 
endonucleases that recognize and cleave long sequences in DNA (Humbert et al). Zinc 
Finger Nucleases are artificial proteins composed of the DNA binding domain of a zinc-
finger protein fused to a Fok1 nuclease domain. TALEs are proteins that are involved in 
direct modulation of gene expression. TALENs on the other hand are those same proteins 
with a Fok1 Nuclease at the end.  
Zinc Finger Nucleases are being phased out right now in favor of TALEs and 
TALENs. This is because Zinc Finger Nucleases are more expensive, more toxic, and not 
as specific as TALEs and TALENs are.  
 TALEs were discovered from the Xanthomonas and Ralstonia bacteria. These 
bacteria developed this resourceful strategy and multiplied and colonized their host 
plants. These bacteria are responsible for the secretion and translocation of effector 
proteins into the host cells. TALEs are made up of a C-terminus, which carries the 
nuclear localization signals, which allows the import of the protein into the nucleus of the 
cell. Downstream of the C-terminus lays an Activation Domain. This activation domain is 
involved in the recruitment of host transcriptional machinery. After that lies the series of 
34 amino acid modules that are repeated in tandem. (Bodnar et al). In these amino acid 
modules lie repeat-variable di-residues (RVDs). Specifically at positions 12 and 13, these 
 3 
RVDs allow for the variation in the TALEs. “…TALEs contain a new and unique kind of 
DNA-binding motif with high sequence specificity. Based on the TALE code, this 
remarkable feature can be exploited to artificially design TALE proteins interacting 
specifically with DNA sequences of interest to modify them by insertion, deletion, or 
other targeted rearrangements.” (Bodnar et al) 
When speaking of TALEs we must also understand the two most important DNA 
repair systems present in eukaryotic cells. These are Non-Homologous end-joining 
(NHEJ) and Homologous Recombination (HR). NHEJ produces DNA sequence changes 
such as deletion/insertion and substitutions in the target sequence. HR occurs when an 
exogenous sequence is introduced into the genome and recombination occurs to allow the 
incorporation of that gene into the target region. This has already been achieved through 
the use of ZFNs. But as mentioned before ZFNs still have major drawbacks. TALEs 
should be able to overcome these drawbacks and become true alternatives. A TALE is 
very specific and has many uses. It can be directed to a promoter region of a gene to 
allow for the induction of that gene, as we are doing. Or you can put an endonuclease at 
the end and cause a double stranded break to incur the gene editing as in TALENs.  
TALEs have a very bright future ahead of them. My research is focused on 
optimizing the construction of those TALEs and to successfully activate the beta globin 
gene. While other papers have shown this to happen, the novelty in my research is the 
further use once we activate the beta globin gene. The use of the molecular beacons to 
specifically detect the sequences of nucleic acids is much understated because that will 
allow us to properly locate the exact location of the sequence in the cell that we want to 
repair. We will then be able to use TALENs to repair the beta globin gene in multiple 
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ways to try and fight sickle cell. While we are still far away from an actual animal model, 
























MATERIALS AND METHODS 
Some of the processes that we use in lab are PCR, Restriction Enzyme Digestion, 
Ligation, and Transformation of the E. coli, Colony Screening, Sequencing and Sequence 
Confirming, and Cell experiments. The methodology of the TALE construction has been 
developed over the past two years.  The workflow is as follows:  
1) Construct TALE Backbone 
2) Construct Backbone with Fluorescence reporter (GFP, CFP, tdTomato, AmCyan) 
3) Sequence confirm the TALEs 
4) Analyze the TALEs in different Cell Lines (293T, K562, HBB::GFP K562) 
5) Compile Data on the effectiveness of the TALEs in the cells 
At this point in the project, work is being done to test the TALEs and different 
combinations of the TALEs to see the effectiveness in the up regulation of the beta globin 
gene. By testing the TALEs in the HBB::GFP K562 cells, we can see exactly how much 
the TALEs actually up regulate the beta globin, since the cells are specifically made to up 











Construct TALE Backbone: 
 
Figure 1. Colony Screen of TALE Backbone Construction  
TALEs were constructed with different length of DNA sequence. TALEs were then 
Colony Screened with a Forward and Reverse primer. TALEs with circles are TALEs 







Construct Backbone with Flourescent Reporters: 
 
Figure 2. Comparison of tdTomato Signal and GFP Signal in 293T cells.  
Above figure shows tdTomato signal compared against GFP signal in certain TALEs. 
TALE A-5 with RT-4 showed the highest signal when compared with the other TALEs 













TALEs are constructed with different reporters to see which reporters have the best 
specificity and sensitivity at the binding site. The tdTomato reporter shows the most 
promise. The reporter, tdTomato, will be used in different reporter systems to see which 
reporter system will show the best results. While we have used 293T, we will also try the 
same results in K562 cells to see if we can replicate the results. Different delivery 
strategies in the cell lines are being investigated. Recent work has shown that 
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